
CERUS CORP — Investor Relations & Filings
Cerus Corporation is a biomedical products company dedicated to safeguarding the world's blood supply. The company develops and commercializes the INTERCEPT Blood System, a pathogen inactivation technology designed to reduce the risk of transfusion-transmitted infections. The system inactivates a broad spectrum of viruses, bacteria, parasites, and leukocytes in donated blood components. It is used for platelets and plasma, with a system for red blood cells in development. Cerus provides its technology to blood centers and hospitals, aiming to establish a new standard of care for blood safety.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - CERUS CORP (0001020214) (Filer) | 2026-04-30 | English | |
| ARS - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | |
| DEF 14A - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | |
| 8-K - CERUS CORP (0001020214) (Filer) | 2026-04-21 | English | |
| SCHEDULE 13G - CERUS CORP (0001020214) (Subject) | 2026-03-24 | English | |
| 10-K - CERUS CORP (0001020214) (Filer) | 2026-03-02 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 39228045 | 10-Q - CERUS CORP (0001020214) (Filer) | 2026-04-30 | English | ||
| 35304984 | ARS - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | ||
| 35305171 | DEF 14A - CERUS CORP (0001020214) (Filer) | 2026-04-22 | English | ||
| 34915401 | 8-K - CERUS CORP (0001020214) (Filer) | 2026-04-21 | English | ||
| 33035200 | SCHEDULE 13G - CERUS CORP (0001020214) (Subject) | 2026-03-24 | English | ||
| 32885386 | 10-K - CERUS CORP (0001020214) (Filer) | 2026-03-02 | English | ||
| 32885385 | 8-K - CERUS CORP (0001020214) (Filer) | 2026-03-02 | English | ||
| 26298646 | 8-K Filing | 2026-01-23 | English | ||
| 26298636 | 8-K Filing | 2026-01-12 | English | ||
|
2025
6 filings
| |||||
| 10764514 | 4 | 2025-11-26 | English | ||
| 10764525 | Regulatory Filings 2025 | 2025-11-24 | English | ||
| 10764515 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 10764521 | 10-Q | 2025-11-06 | English | ||
| 10764523 | 8-K | 2025-11-06 | English | ||
| 10764526 | 4 | 2025-08-25 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CASI Pharmaceuticals, Inc.
Biopharmaceutical firm developing therapeutics for organ tr…
|
CASI | US | Manufacturing |
|
CATALYST PHARMACEUTICALS, INC.
Biopharmaceutical company commercializing drugs for rare ne…
|
CPRX | US | Manufacturing |
|
cbdMD, Inc.
Producer and distributor of health and wellness CBD product…
|
YCBD | US | Manufacturing |
|
CDT Equity Inc.
A clinical-stage biopharmaceutical firm advancing assets fo…
|
CDT | US | Manufacturing |
|
Ceapro Inc.
Develops and commercializes natural active ingredients deri…
|
CZO | CA | Manufacturing |
|
CELADON PHARMACEUTICALS PLC
Researches, cultivates, and manufactures cannabinoid-based …
|
CEL | GB | Manufacturing |
|
Celemics, Inc.
Develops NGS target enrichment solutions for research and c…
|
331920 | KR | Manufacturing |
|
Cellbion Co., Ltd
Develops radiopharmaceuticals and radioligand therapies for…
|
308430 | KR | Manufacturing |
|
CELL BIOTECH CO ., LTD
Develops and manufactures probiotic solutions using patente…
|
049960 | KR | Manufacturing |
|
Celldex Therapeutics, Inc.
Develops antibody-based immunotherapies for severe inflamma…
|
CLDX | US | Manufacturing |
CERUS CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33349/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33349 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33349 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33349 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33349}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CERUS CORP (id: 33349)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.